| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| AMGEN | 12 | 27 | +0,14 % | ||
| AXSOME THERAPEUTICS | 8 | 1 | -0,08 % | ||
| ILLUMINA | 8 | - | -0,80 % | ||
| MODERNA | 6 | 16 | +0,22 % | ||
| PACIRA BIOSCIENCES | 6 | 1 | +0,94 % | ||
| BIONTECH | 5 | 13 | +0,06 % | ||
| BIOGEN | 4 | 54 | -0,36 % | ||
| ALNYLAM PHARMACEUTICALS | 4 | 9 | -1,14 % | ||
| KYMERA THERAPEUTICS | 4 | 6 | 0,00 % | ||
| SYNDAX PHARMACEUTICALS | 4 | 1 | -2,60 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:06 | Phathom Pharmaceuticals to Highlight VOQUEZNA (vonoprazan) at DDW 2026 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 13:54 | Canaccord cuts Illumina stock price target on competition concerns | 1 | Investing.com | ||
| 13:54 | H.C. Wainwright reiterates Biogen stock rating on tau therapy trial | 4 | Investing.com | ||
| 13:54 | Axsome wins FDA label expansion for Auvelity in Alzheimer's agitation | 1 | Seeking Alpha | ||
| 13:42 | Moderna, Inc Q1 Loss Climbs | 185 | AFX News | WASHINGTON (dpa-AFX) - Moderna, Inc (MRNA) revealed Loss for its first quarter of -$1.343 billionThe company's earnings came in at -$1.343 billion, or -$3.40 per share. This compares with -$971... ► Artikel lesen | |
| 13:18 | Viatris presents data on low-dose contraceptive patch at ACOG | 2 | Investing.com | ||
| 13:18 | ARCHIMED to acquire Esperion for up to $1.1 billion | 7 | Investing.com | ||
| 13:18 | Axsome Therapeutics, Inc.: Axsome Therapeutics Hosts AUVELITY FDA Approval Investor Event Featuring Expert Thought Leader | 2 | GlobeNewswire (USA) | ||
| 13:17 | Amgen hebt Jahresprognose an | 2 | cash | ||
| 13:10 | Viatris präsentiert Daten zu niedrig dosiertem Verhütungspflaster auf ACOG-Jahrestagung | 5 | Investing.com Deutsch | ||
| 13:10 | ARCHIMED übernimmt Esperion für bis zu 1,1 Milliarden US-Dollar | 7 | Investing.com Deutsch | ||
| 13:10 | Moderna (MRNA) Reports Q1 Loss, Beats Revenue Estimates | 12 | Zacks | ||
| 13:06 | BofA Securities raises Amgen stock price target on growth drivers | 2 | Investing.com | ||
| 13:06 | Esperion Therapeutics, Inc.: Esperion to be Acquired by ARCHIMED | 21 | GlobeNewswire (Europe) | Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments Represents total equity value of... ► Artikel lesen | |
| 13:06 | Eton Pharmaceuticals relaunches Hemangeol with specialty pharmacy | 2 | Investing.com | ||
| 13:00 | Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces IMCIVREE (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity | 10 | GlobeNewswire (Europe) | -- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired... ► Artikel lesen | |
| 13:00 | Moderna jumps after strong Q1 beat driven by international sales | 22 | Seeking Alpha | ||
| 12:58 | BofA Securities hebt Kursziel für Amgen wegen Wachstumstreibern an | 1 | Investing.com Deutsch | ||
| 12:54 | Eton Pharmaceuticals relaunches HEMANGEOL (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution | 19 | GlobeNewswire (Europe) | HEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiationEton has integrated full Eton Cares patient support, including $0 co-pay for eligible... ► Artikel lesen | |
| 12:38 | Moderna, Inc.: Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates | 245 | ACCESS Newswire | Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports first quarter GAAP net loss of $(1.3) billion and GAAP EPS of $(3.40), including $0.9... ► Artikel lesen |